Literature DB >> 3013402

Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.

P J Loehrer, R Birch, B S Kramer, F A Greco, L H Einhorn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3013402

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  7 in total

Review 1.  New perspectives in lung cancer.5. New drugs in lung cancer.

Authors:  D C Talbot; I E Smith
Journal:  Thorax       Date:  1992-03       Impact factor: 9.139

2.  Phase II trial of ifosfamide in epidermoid carcinoma of the esophagus: unexpectant severe toxicity.

Authors:  D M Nanus; D P Kelsen; R Lipperman; M Eisenberger
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

Review 3.  Systematic review: generating evidence-based guidelines on the concurrent use of dietary antioxidants and chemotherapy or radiotherapy.

Authors:  Akiko Nakayama; Karen P Alladin; Obianuju Igbokwe; Jeffrey D White
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

4.  Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.

Authors:  U Gatzemeier; M Heckmayr; D K Hossfeld; R Zschaber; W Achterrath; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 5.  Single-agent chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; M Clerici; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors.

Authors:  N C Munshi; P J Loehrer; S D Williams; C Langefeld; G Sledge; C R Nichols; B J Roth; A Neuman; W B Walsh; L H Einhorn
Journal:  Invest New Drugs       Date:  1992-08       Impact factor: 3.850

7.  The antioxidant N-acetylcysteine prevents HIF-1 stabilization under hypoxia in vitro but does not affect tumorigenesis in multiple breast cancer models in vivo.

Authors:  Jaclyn Sceneay; Mira C P Liu; Anna Chen; Christina S F Wong; David D L Bowtell; Andreas Möller
Journal:  PLoS One       Date:  2013-06-20       Impact factor: 3.240
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.